Umesh Modi is a chartered accountant, and Pamini Jatheeskumar is a chartered certified accountant at Silver Levene...
  Don Lavoie is alcohol programme manager at Public Health England and Gul Root is lead...
Don Lavoie is alcohol programme manager at Public Health England and Gul Root is lead pharmacist, Health and Wellbeing Directorate, Public Health England
More inWhite Papers  

gepan instillOctober 5 2015

Gepan instill, a potential treatment for cystitis and overactive bladder, has been added to the Drug Tariff. It means people will now be able to treat themselves at home rather than having to go to a hospital clinic, says the UK distributor.

A 40ml pre-filled syringe containing the non-viscous chondroitin sulfate solution 2mg/ml is introduced into the bladder via a catheter, “a straightforward process which can be easily taught to patients,” says Purple Orchid Pharma. The syringe has “an innovative tip that fits directly on to most catheters, and flows easily into the bladder.”

The product can be prescribed for interstitial cystitis, recurrent bacterial cystitis, radiation cystitis and overactive bladder. It “temporarily coats the lining of the bladder, known as the GAG [glycosaminoglycan] layer, sealing over cracks and weaknesses to prevent urine seeping through to the deeper layers and causing inflammation.”

Purple Orchid Pharma also says that Gepan instill compares favourably with tolterodine tartrate in treating overactive bladder syndrome, with a retrospective study concluding there is a more sustained improvement.

“After a year of treatment, 72% of a Gepan instill patients enjoyed reduction of symptoms, as opposed to 43% of those on tolterodine tartrate. Then when the patients were followed up a year after the treatment had stopped, 56% of Gepan patients still had symptom improvements while just 15% of tolterodine patients were able to say the same thing.”

Gepan Instill is listed in the October Drug Tariff part IXA Appliances, where the price for 40ml is £68.00

Gepan Instill     

NHS BSA Drug Tariff    

July 31 2018 General practices employing pharmacists are citing improved capacity to see patients and workload changes as the main benefits of the scheme.
July 25 2018 Switching to sulfonylureas in type 2 diabetes has been linked with an increased risk of complications compared with staying on metformin, a BMJ study has concluded. However, the study has...